Studies | EBMT

Top

Study type

Disease

Group

Type of transplant / Cell therapy

Text

A Phase III Randomized, Placebo-controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-8228 (Letermovir) for the Prevention of Clinically Significant Human Cytomegalovirus (CMV) Infection in Adult, CMV-Seropositive Allogeneic Hematopoietic Stem Cell Transplant Recipients

Clinical Trials Phase I-III

Complications: infectious

Infectious Diseases Working Party (IDWP)

Transplant Complications Working Party (TCWP)

Type of treatment

Principal investigator

Autologous Hematopoietic Stem Cell Transplantation (aHSCT) for Paediatric Multiple Sclerosis

Retrospective Studies

Auto immune disorders

Autoimmune Diseases Working Party (ADWP)

Paediatric Diseases Working Party (PDWP)

Type of treatment

Principal investigator

J Burman, K Kirgizov

Stem Cell Transplantation in blastic plasmocytoid dendritic cell neoplasia. A joint NIS with the ALWP

Non-interventional Prospective Studies

Other myeloid or lymphoid malignancies

Lymphoma Working Party (LWP)

Type of treatment

Principal investigator

Sascha Dietrich, Peter Dreger

Long Term Outcome of a Second Autologous Stem Cell Transplantation for Relapsed/Refractory Hodgkin Lymphoma: A Retrospective Analysis from the Lymphoma Working Party of EBMT

Retrospective Studies

Hodgkin’s Disease (HD)

Lymphoma Working Party (LWP)

Type of treatment

Principal investigator

Allogeneic Stem Cell Transplantation for cutaneous T-cell lymphoma

Non-interventional Prospective Studies

Non-Hodgkin’s Lymphoma (NHL)

Lymphoma Working Party (LWP)

Type of treatment

Principal investigator

Checkpoint inhibition for treating Hodgkin and Non-Hodgkin lymphoma in the context of allogeneic stem cell transplantation: A survey-based registry study of the EBMT Lymphoma Working Party.

Retrospective Studies

Hodgkin’s Disease (HD)

Non-Hodgkin’s Lymphoma (NHL)

Lymphoma Working Party (LWP)

Type of treatment

Principal investigator

Elderly AML: A randomised Phase III study comparing conventional chemotherapy to low dose total body irradiation-based conditioning and hematopoietic stem cell transplantation from related and unrelated donors as consolidation therapy for older patients with AML in 1st complete remission

Clinical Trials Phase I-III

Acute Myeloid Leukaemia (AML)

Acute Leukemia Working Party (ALWP)

Type of treatment

Principal investigator

Dietger Niederwieser